George Kramer, MD
Cardiovascular Disease · Marietta, GANPI 1720056443
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,948 of the $55,279 with a category attached, or 86.7%. Johnson & Johnson accounts for 91.1% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2023 at $15,289 and has fallen 95.6% since, to $667 in 2025. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 270 payments — averaging $204.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$50K
- Novartis$671
- Boehringer Ingelheim$552
- Heartflow, Inc.$392
- E.r. Squibb & Sons, L.L.C.$373
- Pfizer$331
- plus $3K from 19 others
Across 2 payments — averaging $3732.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Canada Ltd.ltee$6K
- Lilly USA, LLC$1K
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$47,94887%
- Travel & lodging$1,1162%
- Food & beverage$5,91511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 62 | $50,348 |
| Novartis | 32 | $671 |
| Boehringer Ingelheim | 28 | $552 |
| Heartflow, Inc. | 4 | $392 |
| E.r. Squibb & Sons, L.L.C. | 18 | $373 |
| Pfizer | 17 | $331 |
| Merck | 17 | $301 |
| Esperion Therapeutics, Inc. | 14 | $281 |
| Boston Scientific | 6 | $229 |
| Amgen | 11 | $210 |
| AstraZeneca | 11 | $204 |
| Medtronic(2 entities) | 3 | $202 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $192 |
| Cvrx, Inc. | 3 | $159 |
| Amarin Pharma, Inc. | 8 | $132 |
| Bayer | 6 | $108 |
| W. L. Gore & Associates, Inc. | 6 | $107 |
| Novo Nordisk | 5 | $103 |
| Abbott | 1 | $92 |
| Philips North America LLC | 1 | $82 |
| Sanofi-aventis U.S. LLC | 3 | $67 |
| Actelion Pharmaceuticals US, Inc. | 3 | $62 |
| Bristol Myers Squibb | 2 | $41 |
| Edwards Lifesciences | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$49,562
- FFRct$336
- SYMPLICITY G3$163
How this compares
$55,279 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 370 | $464,911 |
| XareltoRivaroxaban | 107 | $116,527 |
| EntrestoSacubitril/Valsartan | 34 | $51,658 |
| JardianceEmpagliflozin | 31 | $42,012 |
| Praluent PenAlirocumab | 44 | $33,234 |
| Repatha SureclickEvolocumab | 17 | $24,306 |
| VascepaIcosapent Ethyl | 22 | $10,195 |
| FarxigaDapagliflozin Propanediol | 12 | $8,788 |
| Ranolazine ErRanolazine | 50 | $5,873 |
| Rosuvastatin Calcium | 518 | $4,233 |
| Metoprolol Succinate | 340 | $4,144 |
| Atorvastatin Calcium | 406 | $3,330 |
| Potassium Chloride | 167 | $2,839 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 146 | $2,678 |
| ClopidogrelClopidogrel Bisulfate | 230 | $2,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $331 | $464,911370 claims |
| Johnson & JohnsonXarelto | $50,348 | $116,527107 claims |
| NovartisEntresto | $671 | $51,65834 claims |
| Boehringer IngelheimJardiance, Pradaxa | $552 | $44,19643 claims |
| AstraZenecaFarxiga | $204 | $8,78812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Marietta
- Dhaval PatelMarietta$67K
- Narendra SinghJohns Creek$1.6M
- Hunter ChampionColumbus$1.5M
- Nicolas ChronosEatonton$912K
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Kashyap ChoksiThomasville$263K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Hiren ShahColumbus$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.